Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Clinical and Molecular Rersponse of Pyoderma Gangrenosum to Interleukin 23 Blockade: results from a proof-of-concept open-label clinical trial

ABSTRACT: The Clinical and Molecular Rersponse of Pyoderma Gangrenosum to Interleukin 23 Blockade: results from a proof-of-concept open-label clinical trial

PROVIDER: PRJNA1132523 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The Clinical and Molecular Rersponse of Pyoderma Gangrenosum to Interleukin 23 Blockade: results from a proof-of-concept open-label clinical trial

Project description:Open Label Clinical Trial

2024-07-09 | GSE271627 | GEO

Exploring kidney allograft rejection: A proof-of-concept study using spatial transcriptomics

Project description:Exploring kidney allograft rejection: A proof-of-concept study using spatial transcriptomics

| PRJNA1030317 | ENA

Proof of concept of blockmiR induced MBNL rescue in Myotonic dystrophy muscle cells

Project description:Proof of concept of blockmiR induced MBNL rescue in Myotonic dystrophy muscle cells

| PRJNA725240 | ENA

Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study

Project description:Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study

| PRJNA734648 | ENA

In vitro transcription studies used in a proof of concept whole transcriptome model predition study

Project description:In vitro transcription studies used in a proof of concept whole transcriptome model predition study

| PRJNA431283 | ENA

Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial

Project description:To assess the safety, efficacy, and molecular change associated with treatment of patients with early, diffuse cutaneous systemic sclerosis (dcSSc) with nilotinib (Tasigna™). In this open-label pilot trial 6 adult patients with early dcSSc received nilotinib. Primary endpoints were safety and change in modified Rodnan Skin Score (MRSS) after 6 months. Lesional skin biopsies at baseline, 6 and 12 months of treatment were assessed by histopathology, immunohistochemistry, and DNA microarray.

2015-08-27 | E-GEOD-65405 | biostudies-arrayexpress

Exploring kidney allograft rejection: A proof-of-concept study using spatial transcriptomics

Project description:In this proof-of-concept study, spatial transcriptomics combined with public single-cell RNA sequencing data were used to explore the potential of this technology to study kidney allograft rejection. We aimed to map gene expression patterns within diverse pathological states by examining biopsies classified across non-rejection, T cell-mediated acute rejection, and interstitial fibrosis and tubular atrophy (IFTA). Our results revealed distinct immune cell signatures, including those of T and B lymphocytes, monocytes, mast cells, and plasma cells, and their spatial organization within the renal interstitium. We also mapped chemokine receptors and ligands to study immune-cell migration and recruitment. Finally, our analysis demonstrated differential spatial enrichment of transcription signatures associated with kidney allograft rejection across various biopsy regions. Interstitium regions displayed higher enrichment scores for rejection-associated gene expression patterns than did tubular areas, which had negative scores. This implies that these signatures are primarily driven by processes unfolding in the renal interstitium. Overall, this study highlights the value of spatial transcriptomics for revealing cellular heterogeneity and immune signatures in renal transplant biopsies, and demonstrates its potential for studying the molecular and cellular mechanisms associated with rejection. However, certain limitations must be borne in mind regarding the development and future applications of this technology.

2024-05-02 | GSE245870 | GEO

Sterilization of female rats by single-injection of estrogen: proof-of-concept for a nonsurgical alternative

Project description:Sterilization of female rats by single-injection of estrogen: proof-of-concept for a nonsurgical alternative

| PRJNA912242 | ENA

Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study.

Project description:Cellular therapy is an emerging therapeutic modality with a great potential for the treatment of autism. Recent findings show that the major underlying pathogenetic mechanisms of autism are hypoperfusion and immune alterations in the brain. So conceptually, cellular therapy which facilitates counteractive processes of improving perfusion by angiogenesis and balancing inflammation by immune regulation would exhibit beneficial clinical effects in patients with autism. This is an open label proof of concept study of autologous bone marrow mononuclear cells (BMMNCs) intrathecal transplantation in 32 patients with autism followed by multidisciplinary therapies. All patients were followed up for 26 months (mean 12.7). Outcome measures used were ISAA, CGI, and FIM/Wee-FIM scales. Positron Emission Tomography-Computed Tomography (PET-CT) scan recorded objective changes. Out of 32 patients, a total of 29 (91%) patients improved on total ISAA scores and 20 patients (62%) showed decreased severity on CGI-I. The difference between pre- and postscores was statistically significant (P < 0.001) on Wilcoxon matched-pairs signed rank test. On CGI-II 96% of patients showed global improvement. The efficacy was measured on CGI-III efficacy index. Few adverse events including seizures in three patients were controlled with medications. The encouraging results of this leading clinical study provide future directions for application of cellular therapy in autism.

| S-EPMC3767048 | biostudies-literature

Pre-clinical proof of principle for orally delivered Th17 antagonist miniproteins

Project description:Pre-clinical proof of principle for orally delivered Th17 antagonist miniproteins

| PRJNA1096346 | ENA